A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms HAWK
  • Sponsors Alcon
  • Most Recent Events

    • 20 Jun 2017 According to a Novartis media release, detailed analysis of the data is ongoing and will be presented at an upcoming medical congress.
    • 20 Jun 2017 Primary endpoint has been met. (Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 48), as reported in a Novartis media release.
    • 20 Jun 2017 Results published in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top